General Wellness or Medical Device? Unaddressed Implications of the FDA's 2026 Guidance

In January 2026, the US Food and Drug Administration (FDA) issued updated guidance on General Wellness: Policy for Low-Risk Devices. As consumer wearable technologies increasingly measure physiologic parameters traditionally associated with clinical care, such as blood pressure and oxygen saturation, the regulatory distinctions between wellness and medical devices have become ever more important in terms of safety, innovation, and healthcare integration. The objective of this comment is to evaluate the regulatory and clinical implications of the FDA's 2026 General Wellness Guidance, with emphasis on validation standards, informational and behavioral safety risks, definitional boundaries between wellness and medical devices, and downstream effects on healthcare integration. The 2026 guidance permits general wellness products to display clinically analogous values if "validated" but does not define minimum methodological standards. Review of regulatory text and published validation frameworks identified four principal gaps: (1) insufficiently defined validation requirements for outputs that mimic clinical measurements; (2) unaddressed informational and behavioral safety risks; (3) internal inconsistencies in definitional boundaries between wellness and medical use; and (4) risk of market fragmentation that may simultaneously increase consumer confusion and impede long-term clinical integration. We argue that without clearer validation standards, transparency requirements, and structured pathways from wellness innovation to clinical application, the guidance risks creating a two-tier digital health ecosystem with unintended downstream consequences for consumer safety and clinical integration. Regulatory clarity must balance innovation with consumer protection and equitable healthcare access. Along these lines, we propose specific guidance refinements to strengthen validation standards, address informational risk, and support the responsible evolution of consumer wearables into clinically integrated tools.

Duke Scholars

Author Jessilyn Dunn Biomedical Engineering

Author Anita Shlesinger